Skip to content

Transareolar single-port endoscopic thoracic sympathectomy with a flexible endoscope for primary palmar hyperhidrosis: a randomized controlled trial.

Transareolar single-port endoscopic thoracic sympathectomy with a flexible endoscope for primary palmar hyperhidrosis: a randomized controlled trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020762
Enrollment
Unknown
Registered
2019-01-18
Start date
2019-01-18
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary palmar hyperhidrosis

Interventions

Group 1:transareolar single-port endoscopic thoracic sympathectomy with a flexible endoscope
Group2:traditional transaxillary single-port

Sponsors

First Affiliated Hospital, Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
16 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 16 to 50 years; 2. Male patients with severe palmar hyperhidrosis that significantly affects their daily life; 3. Absence of history of thoracic surgery and severe chest wall deformity; 4. No contraindication for anaesthetic procedure with single-lumen endotracheal intubation.

Exclusion criteria

Exclusion criteria: 1. Plantar, axillary hyperhidrosis without palmar hyperhidrosis; 2. Lung, pleural and heart diseases that could increase surgical risk; 3. Secondary hyperhidrosis including hyperthyroidism, acute and chronic infections, malignancy, and immunologic disorders.

Design outcomes

Primary

MeasureTime frame
postoperative pain score;Cosmetic results;resolution of symptoms;Postoperative complications;

Secondary

MeasureTime frame
incision length;Satisfaction;

Countries

China

Contacts

Public ContactTu Yuanrong

First Affiliated Hospital, Fujian Medical University

tuyuanrongmd@163.com+86 13705911716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026